FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]

Nur für Forschungszwecke. Vollständige Erklärung →

Forschung/Highlighting the differential risk profiles of various GLP-1 receptor agonists for gastrointestinal adverse events based on real-world data, emphasizing implications for clinical practice.
Zurück zur Forschungsbibliothek
GLP-1 receptor agonistsexenatideliraglutidedulaglutidelixisenatidesemaglutide

Highlighting the differential risk profiles of various GLP-1 receptor agonists for gastrointestinal adverse events based on real-world data, emphasizing implications for clinical practice.

May 17, 2026
Share

Quellpapier

Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.

Liu Lulu et al.Frontiers in endocrinology2022
Emergierende Forschung

Basiert auf emergierender Forschung. Diese Erkenntnisse sind versprechend, aber erfordern weitere Validierung.

Über diese Analyse

Diese Artikel zerlegen die Ergebnisse des obigen Quellpapiers in verständliche Sprache für die Peptidforschungscommunity. Unser Ziel ist es, das Wichtigste hervorzuheben — die praktischen Implikationen, den Stärke der Beweise und was dies für laufende Forschung bedeutet.

Navigating Gastrointestinal Risks with GLP-1 Receptor Agonists: A Real-World Perspective

Published: May 17, 2026 | Source: Frontiers in endocrinology (2022) | Category: GLP-1 receptor agonists, exenatide, liraglutide, dulaglutide, lixisenatide, semaglutide

Overview

A recent study published in Frontiers in Endocrinology has shed light on the varying gastrointestinal adverse event profiles of different glucagon-like peptide-1 receptor agonists (GLP-1 RAs) used for diabetes management. The research highlights that while these medications offer significant benefits, they come with distinct risks of side effects such as nausea and abdominal pain, which can vary widely between brands.

Study Background

GLP-1 RAs have become a cornerstone in the treatment of type 2 diabetes due to their efficacy in improving glycemic control. However, despite their widespread use, there has been limited real-world data on how these drugs compare when it comes to gastrointestinal side effects. This study aimed to fill that gap by analyzing adverse event reports collected from the U.S. FDA Adverse Event Reporting System (FAERS) database.

What the Research Found

The study analyzed over 21,000 gastrointestinal toxicity reports among users of five GLP-1 RAs: exenatide, liraglutide, dulaglutide, lixisenatide, and semaglutide. The findings revealed that all GLP-1 RAs were associated with an increased risk of gastrointestinal system disorders compared to other medications. However, the risks varied significantly between different drugs:

  • Semaglutide: Showed the highest risk for nausea (ROR 7.41), diarrhea (ROR 3.55), vomiting (ROR 6.67), and constipation (ROR 6.17).
  • Liraglutide: Had the greatest risk of upper abdominal pain (ROR 4.63) and pancreatitis (ROR 32.67).

Moreover, liraglutide had the highest severe rate of gastrointestinal AEs at 23.31%, indicating a higher likelihood of serious complications.

What This Means for Peptide Users

For patients considering GLP-1 RAs as part of their diabetes management plan, this research underscores the importance of discussing potential side effects with healthcare providers. The varying risk profiles among different GLP-1 RAs suggest that choosing the right medication based on individual tolerance to gastrointestinal symptoms is crucial.

Limitations and Caveats

While the study provides valuable insights into real-world risks associated with GLP-1 RAs, it relies heavily on adverse event reports which can be biased due to underreporting or overreporting. Additionally, the lack of detailed clinical context means that patient-specific factors such as medical history and concurrent medications could influence outcomes.

How This Compares to Previous Research

Previous studies have also noted gastrointestinal side effects with GLP-1 RAs but often focused on specific symptoms rather than comparing across different drugs. This study's comprehensive approach offers a more nuanced understanding of the comparative risks, aligning with earlier findings while providing new insights into differential risk profiles.

Our Analysis

PeptideVault views this research as an important step towards better-informed clinical decision-making regarding GLP-1 RAs. The detailed analysis of adverse event data provides a practical tool for healthcare providers and patients to navigate the complexities of these medications more effectively. However, it is crucial to interpret these findings in conjunction with other clinical evidence and patient-specific factors.

Key Takeaways

  • Differential Risks: GLP-1 RAs have varying gastrointestinal risk profiles.
  • Patient-Centric Approach: Choosing a GLP-1 RA based on individual tolerance to side effects can improve treatment outcomes.
  • Further Research Needed: More detailed clinical studies are required to fully understand the implications of these findings.

Original Source

Citation: Liu Lulu, Chen Jia, Wang Lei et al. (2022). Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.. Frontiers in endocrinology. DOI: 10.3389/fendo.2022.1043789

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Bearbeitungsnotiz

Diese Analyse wurde vom Peptide Contacts-Forscherteam erstellt. Wir ermutigen Leser, die volle Quellpapier für vollständige Methoden und Daten. Die ursprüngliche Veröffentlichung ist auf PubMed.

Verwandte Forschungen

Comments

Sign in to join the discussion

Diese Analyse basiert auf peer-bewerteter Forschung zur Bildungszwecke. Sie bildet keine medizinische Beratung aus. Stets beraten Sie sich mit einer qualifizierten Gesundheitsversorgerin, bevor Sie irgendeine Peptidbasierte Therapie verwenden.